Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your DNA may decide how well exercise and diet work for weight loss

NCT ID NCT07750197

Knowledge-focused Sponsor: Harbin Sport University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study is testing whether a specific gene variant (MC4R rs17782313) and metabolic health status influence how men with obesity respond to a 12-week exercise and diet program. Forty men aged 18 to 59 with obesity will be classified as having metabolically healthy or unhealthy obesity, then all will receive the same supervised lifestyle intervention. Researchers will measure changes in body weight, body composition, and various health markers to see if responses differ based on genetics and metabolic phenotype.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A 12-week supervised program combining aerobic exercise, resistance training, and an individualized energy-controlled diet.
What this could lead to
If successful, this could help tailor exercise and diet programs based on a person's genetic makeup and metabolic health, making weight loss efforts more effective.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply to everyone. The outcome depends on individual adherence and biological variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Mar 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 59 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male sex * Age 18 to 59 years * Body mass index of at least 28 kg/m2 * Waist circumference of at least 90 cm * Able and willing to provide written informed consent * Able and willing to participate in the 12-week supervised exercise and dietary intervention and complete the scheduled assessments Exclusion Criteria: * Severe hepatic insufficiency * Severe renal insufficiency * Cardiovascular disease * Other clinically significant vascular disease * Current use of glucose-lowering medication * Current use of antihypertensive medication * Current use of lipid-lowering medication * Unable or unwilling to comply with the intervention and assessment schedule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolically healthy obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple endocrine neoplasia type 1 Obesity obesity disorder Obesity, Metabolically Benign

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolically healthy obesity Metabolically unhealthy obesity Obesity

Contacts and locations

Locations

  • Harbin Sport University

    Harbin, Heilongjiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.